PT-141 and gender-affirming hormones: what we know about sexual desire
In this article
You can ask about PT-141 while receiving gender-affirming care. Whether it helps with hormone-associated changes in desire has not been established in the clinical research identified here. Clinicians have proposed bremelanotide, also called PT-141, as a possible option for transgender women while emphasizing the need for evidence. Clinician review.
Your gender goals and your sexual wellbeing both belong in that conversation. If interest in sex changes, you can explore what would help without treating your transition itself as the problem.
Desire can change without following one predictable path
An early change in desire does not necessarily describe the years ahead. In the prospective ENIGI study, desire scores initially decreased in transgender women and increased in transgender men. At three years, total and partnered desire were above baseline in transgender women and comparable with baseline in transgender men. Individual experiences can differ, and the study did not test PT-141. ENIGI study.
That leaves room for your actual experience. You might welcome a lower level of spontaneous desire. You might miss it. You might want different kinds of intimacy, or feel desire in different circumstances than before. The question is what matters to you and whether a change is causing difficulty you want help with.
You do not have to describe the goal as getting your previous sex life back. It can be finding a sexual life that fits who you are now.
Why PT-141 enters the conversation
Bremelanotide activates melanocortin receptors rather than replacing estrogen or testosterone. The precise mechanism of its benefit in hypoactive sexual desire disorder, or HSDD, is not fully established. That distinction helps explain the interest in it, but does not prove a benefit for hormone-associated desire changes. Vyleesi prescribing information.
A 2021 clinician review included bremelanotide among possible approaches for transgender women, alongside sex therapy and other medications. It called for an assessment of biological, psychological, and social factors and highlighted missing treatment-efficacy data. Cocchetti and colleagues.
For transgender men and nonbinary people using different hormone regimens, the specific treatment question also remains unresolved. Discuss the evidence in relation to your own regimen and goals.
Which evidence applies, and which does not?
Vyleesi, the FDA-approved bremelanotide product, has a specific indication for premenopausal women with acquired, generalized HSDD. Its indication excludes low desire caused by another medical or psychiatric condition, a relationship problem, or a medication or drug substance. That is a different evidence question from a change associated with gender-affirming treatment. Current label.
A gender label alone does not establish how a study applies to someone’s hormone regimen, anatomy, medical history, or goals.
AnthologyRX’s compounded PT-141 contains bremelanotide, the active ingredient in Vyleesi. A licensed pharmacy prepares it to an individual prescription. The finished preparation is not FDA-approved or established as equivalent to Vyleesi in safety, effectiveness, or quality. Treatment details; FDA compounding explanation.
Start by describing what has changed
Bring your clinician a description in your own words. These prompts can help organize it:
- Interest: Do you want sex less often, think about it less, or have trouble feeling interested even when you want to?
- Context: Is the change present alone, with a partner, or only in particular situations?
- Physical experience: Is the concern desire, arousal, erection, lubrication, orgasm, sensation, discomfort, or a combination?
- Timing: Did it begin around a medication change, surgery, another health issue, or a change in your life?
- Your goal: What would feel like a worthwhile improvement to you?
Sexual function and satisfaction belong within gender-affirming care. The European Society for Sexual Medicine includes them in its assessment and hormonal-management guidance. ESSM position statement.
If your questions involve antidepressant-related changes or difficulty reaching orgasm, those guides can help you describe the concern. Neither assumes that hormones explain everything.
Can PT-141 be combined with my hormones?
There is no blanket answer that covers every estrogen, testosterone, antiandrogen and other medication regimen. A lack of direct trial evidence does not establish either compatibility or a specific harmful interaction.
Bring a complete medication list, including hormone doses and routes. Vyleesi can temporarily raise blood pressure, lower heart rate, and cause nausea. It is contraindicated with uncontrolled hypertension or known cardiovascular disease and can affect oral medication absorption. That warning does not establish an interaction with a particular hormone regimen; the actual combination needs review. Prescribing information.
Coordinate changes with the clinician managing your hormones. Do not stop or adjust them on the basis of a product page. Our PT-141 safety guide covers additional medication risks.
Questions worth bringing to the appointment
- Which options address the change I want help with, and what evidence supports them?
- How would the proposed treatment fit with my hormone regimen and other medications?
- How will we assess benefit and coordinate follow-up with the clinician managing my hormones?
Exploring PT-141 through AnthologyRX
AnthologyRX can assess PT-141 for people receiving gender-affirming care elsewhere. Include your hormone regimen, other medications, and what you want help with so the reviewing clinician can evaluate suitability.
AnthologyRX does not provide gender-affirming care or manage your hormone regimen. Continue that care with your existing clinician and discuss how any proposed treatment would fit alongside it.
For more background, read the PT-141 evidence guide.
